Griffiths reports 21.7% stake in Silence Therapeutics

Rhea-AI Filing Summary

Silence Therapeutics plc large shareholder Richard Griffiths has updated his ownership in an Amendment No. 10 to his Schedule 13D. He now beneficially owns 30,844,458 ordinary shares, representing 21.7% of the company’s ordinary shares, based on 141,701,847 shares outstanding in the issuer’s last SEC filing.

The filing explains that this amendment reflects open-market transactions in the issuer’s American Depositary Shares (ADSs) together with dilution from an increase in share capital. Griffiths sold an aggregate of 1,544,374 ADSs between June 29, 2026 and July 6, 2026 for aggregate sales proceeds of $16. Each ADS represents, and at the holder’s option is convertible into, three ordinary shares of the issuer.

Key Figures

Beneficial ownership: 30,844,458 ordinary shares Ownership percentage: 21.7% Ora Capital holding: 19,155,522 ordinary shares +4 more

7 metrics

Beneficial ownership 30,844,458 ordinary shares Shares beneficially owned by Richard Griffiths

Ownership percentage 21.7% Portion of Silence Therapeutics ordinary shares held by Griffiths

Ora Capital holding 19,155,522 ordinary shares Shares represented by ADSs held by Ora Capital Limited

Ora Capital ownership percentage 13.5% Portion of ordinary shares attributed to Ora Capital Limited

Shares outstanding 141,701,847 ordinary shares Issuer’s outstanding ordinary shares used for percentage calculations

ADSs sold 1,544,374 ADSs Aggregate ADSs sold in open market between June 29 and July 6, 2026

Aggregate sales proceeds $16 Total proceeds stated for 1,544,374 ADSs sold

Key Terms

American Depositary Shares, beneficially owned, sole voting power, Schedule 13D, +1 more

5 terms

American Depositary Shares financial

"Consists of ordinary shares represented by American Depositary Shares ("ADSs")"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

beneficially owned financial

"Aggregate amount beneficially owned by each reporting person 30,844,458.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: Sole Voting Power 30,844,458.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Schedule 13D regulatory

"This Amendment No. 10 to ... which amends and supplements the filed ... on Schedule 13D"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

Joint Filing Agreement regulatory

"Joint Filing Agreement as required by Rule 13d-1(k)(1)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake does Richard Griffiths report in Silence Therapeutics (SLN)?

Richard Griffiths reports beneficial ownership of 30,844,458 ordinary shares of Silence Therapeutics, representing 21.7% of the outstanding ordinary shares, based on 141,701,847 shares disclosed in the issuer’s last SEC filing. This reflects his current reported position as of the amendment.

How many Silence Therapeutics ADSs did Richard Griffiths sell in this period?

Richard Griffiths sold an aggregate of 1,544,374 American Depositary Shares (ADSs) in open-market transactions between June 29, 2026 and July 6, 2026. The filing describes these as open market sales of the issuer’s ADSs, not new purchases or grants.

What percentage of Silence Therapeutics does Ora Capital Limited hold?

Ora Capital Limited, an entity controlled by Richard Griffiths, beneficially owns 19,155,522 ordinary shares of Silence Therapeutics, representing 13.5% of the outstanding ordinary shares. These shares are represented by ADSs held directly by Ora Capital Limited, according to the filing.

How are Silence Therapeutics ADSs related to its ordinary shares?

Each Silence Therapeutics American Depositary Share (ADS) represents three ordinary shares of the issuer and, at the holder’s option, is convertible into three ordinary shares. This ADS-to-share ratio is explicitly stated in the disclosure about the reporting person’s holdings.

Which entities hold Silence Therapeutics shares for Richard Griffiths?

The filing lists holdings through several entities: Ora Capital Limited, Sarossa Plc, Cream Capital Limited, Blake Holdings Limited, Ora Ventures Limited, Pinkey's Limited, and shares held directly by Mr. Griffiths. He is a director or controlling shareholder of these entities and can direct voting and disposition.

What is the total share count used to calculate Richard Griffiths’ 21.7% stake in SLN?

The 21.7% beneficial ownership figure is calculated using 141,701,847 outstanding ordinary shares of Silence Therapeutics. This outstanding share count comes from the issuer’s last SEC filing and is used as the basis for all reported percentage holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 07:00 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 10)

Silence Therapeutics Plc

(Name of Issuer)

Ordinary Shares, nominal value of PS0.05 per share

(Title of Class of Securities)

G8128Y157

(CUSIP Number)

Richard Griffiths
19-21, Broad Street
St Helier, Y9, JE2 3RR
44 1534 517500

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/06/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): G8128Y157

1

Name of reporting person

Richard Griffiths

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

JERSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 30,844,458.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 30,844,458.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

30,844,458.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

21.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

* Consists of (i) 19,155,522 ordinary shares represented by American Depositary Shares ("ADSs") held by Ora Capital Limited; (ii) 1,815,522 ordinary shares represented by ADSs held by Sarossa Plc; (iii) 3,000,000 ordinary shares represented by ADSs held by Cream Capital Limited; ; (iv) 300,000 ordinary shares represented by ADSs held by Blake Holdings Limited; (v) 360,000 ordinary shares represented by ADSs held by Ora Ventures Limited; (vi) 190,500 ordinary shares represented by ADSs held by Pinkey's Limited; and (vii) 6,022,914 ordinary shares represented by ADSs held by Mr. Griffiths. Each ADS represents, and at the holder's option is convertible into, three ordinary shares of the Issuer. Mr. Griffiths is a director and the controlling shareholder of each of Ora Capital Limited, Ora Ventures Limited, Blake Holdings Limited, Sarossa Plc and Cream Capital Limited and a controlling shareholder of Pinkey's Limited and possesses the power to direct the voting and disposition of these shares. **This percentage is calculated based upon the 141,701,847 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing.

SCHEDULE 13D

CUSIP Number(s): G8128Y157

1

Name of reporting person

Ora Capital Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

JERSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 19,155,522.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 19,155,522.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

19,155,522.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

13.5 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

* Consists of 19,155,522 ordinary shares represented by ADSs held by Ora Capital Limited. **This percentage is calculated based upon the 141,701,847 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, nominal value of PS0.05 per share
(b)	Name of Issuer: Silence Therapeutics Plc
(c)	Address of Issuer's Principal Executive Offices: 72 Hammersmith Road, London, UNITED KINGDOM , W14 8TH.
Item 1 Comment: This Amendment No. 10 to Schedule 13D (this "Amendment"), which amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on June 15, 2022, as amended on July 20, 2022, October 20, 2022, August 14, 2023, March 27, 2024, December 18, 2024, March 31, 2025, April 24, 2025, May 8, 2025 and June 25, 2025 (the "Schedule 13D") on behalf of Richard Ian Griffiths, relates to the ordinary shares, nominal value PS0.05 per share (the "Shares"), of Silence Therapeutics plc (the "Issuer"). This Amendment is being filed to reflect the open market transactions of the Issuer's ADSs by the Reporting Person together with dilution as a result of an increase in the share capital of the Issuer. Except as amended and supplemented hereby, the Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Schedule 13D.
Item 2.	Identity and Background
(a)	Richard Griffiths
(b)	19-21 Broad Street, St Helier, Jersey, JE2 3RR
(d)	n/a
(e)	n/a
(f)	Jersey, Channel Islands
Item 3.	Source and Amount of Funds or Other Consideration
	Mr. Griffiths sold an aggregate of 1,544,374 ADSs in open market transactions between June 29, 2026 and July 6, 2026 for aggregate sales proceeds of $16.3M.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	n/a
Item 7.	Material to be Filed as Exhibits.
	A. Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. B. Schedule 1 Transactions in ADSs During the Past Sixty Days

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Richard Griffiths

Signature:	/s/ Richard Ian Griffiths
Name/Title:	Richard Ian Griffiths
Date:	07/07/2026

Ora Capital Limited

Signature:	/s/ Richard Ian Griffiths
Name/Title:	Director
Date:	07/07/2026